A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18–60 years of age) with chronic diseases who are at risk of post-influenza complicationsVaccine, 2007
- The Boomers Are Coming: A Total Cost of Care Model of The Impact of Population Aging on The Cost of Chronic Conditions in The United StatesDisease Management, 2007
- Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trialThe Lancet, 2006
- The Boomers Are Coming: A Total Cost of Care Model of the Impact of Population Aging on Health Care Costs in the United States by Major Practice CategoryHealth Services Research, 2006
- Vaccines for preventing influenza in the elderly2006
- The unmet need in the elderly: Designing new influenza vaccines for older adultsVaccine, 2005
- InfluenzaThe Lancet, 2003
- Toward Consistency in Cost-Utility AnalysesMedical Care, 1998
- Clinical effectiveness of influenza vaccination in Manitoba1993
- The utility of different health states as perceived by the general publicJournal of Chronic Diseases, 1978